Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.83 |
| ▸ | PLA2G4A | P47712 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777023 | 1.00 | METTL3 (0.83) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL1044577 | 0.93 | METTL3 (0.86) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL1044579 | 0.93 | METTL3 (0.86) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL29623981 | 0.91 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL726251 | 0.91 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL726252 | 0.91 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL13225651 | 0.91 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL15068363 | 0.90 | METTL3 (0.86) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL1042832 | 0.90 | METTL3 (0.86) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL17341018 | 0.90 | METTL3 (0.78) | METTL3PLA2G4AMAPTGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1978960-A1 | USE OF 6-(3-CHLORO-2-FLUOROBENZYL)-1-Ý(2S)-1-HYDROXY-3-METHYLBUTAN-2-YL¨-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID OR SALT THEREOF FOR TREATING RETROVIRUS INFECTION | JAPAN TOBACCO INC. (JP) | 2008-10-15 | — | — | EP | claimed |
| WO-2007089030-A1 | USE OF 6-(3-CHLORO-2-FLUOROBENZYL)-1-[(2S)-1-HYDROXY-3-METHYLBUTAN-2-YL]-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID OR SALT THEREOF FOR TREATING RETROVIRUS INFECTION | JAPAN TOBACCO INC. (JP) | 2007-08-09 | — | — | WO | claimed |
| US-20140343063-A1 | METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS | GILEAD SCIENCES, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| EP-1978960-A1 | USE OF 6-(3-CHLORO-2-FLUOROBENZYL)-1-Ý(2S)-1-HYDROXY-3-METHYLBUTAN-2-YL¨-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID OR SALT THEREOF FOR TREATING RETROVIRUS INFECTION | JAPAN TOBACCO INC. (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089030-A1 | USE OF 6-(3-CHLORO-2-FLUOROBENZYL)-1-[(2S)-1-HYDROXY-3-METHYLBUTAN-2-YL]-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID OR SALT THEREOF FOR TREATING RETROVIRUS INFECTION | JAPAN TOBACCO INC. (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343063-A1 | METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS | CYP3A43, CYP3A7, CYP3A5 | METTL3 736/4885PLA2G4A 3969/4885MAPT 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.